28 results on '"Kesselheim, Aaron S."'
Search Results
2. Regulating Off-Label Promotion - A Critical Test.
3. Pharmaceutical Promotion to Physicians and First Amendment Rights.
4. The 21st Century Cures Act -- Will It Take Us Back in Time?
5. User Fees and Beyond — The FDA Safety and Innovation Act of 2012.
6. Pharmaceutical Marketing and the New Social Media.
7. Incentives for Drug Development — The Curious Case of Colchicine.
8. The Supreme Court, Preemption, and Malpractice Liability.
9. Drug Development for Neglected Diseases — The Trouble with FDA Review Vouchers.
10. A New Way to Contain Unaffordable Medication Costs - Exercising the Government's Existing Rights.
11. The 21st Century Cures Act.
12. The Watchman Saga -- Closure at Last?
13. The FDA Breakthrough-Drug Designation - Four Years of Experience.
14. Speed, Safety, and Industry Funding - From PDUFA I to PDUFA VI.
15. Reputation and Precedent in the Bevacizumab Decision.
16. The Regulatory Accountability Act of 2017 - Implications for FDA Regulation and Public Health.
17. Forbidden and Permitted Statements about Medications -- Loosening the Rules.
18. High-Cost Generic Drugs — Implications for Patients and Policymakers.
19. Ensuring Access to Injectable Generic Drugs - The Case of Intravesical BCG for Bladder Cancer.
20. FDA Regulation of Mobile Health Technologies.
21. New FDA Breakthrough-Drug Category -- Implications for Patients.
22. Regulation of Medical Devices in the United States and European Union.
23. Progress and Hurdles for Follow-on Biologics.
24. Using a Drug-Safety Tool to Prevent Competition.
25. Revisiting FDA Approval of Aducanumab.
26. The 21st Century Cures Act.
27. Practical, Legal, and Ethical Issues in Expanded Access to Investigational Drugs.
28. New FDA Breakthrough-Drug Category -- Implications for Patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.